Clinical observation of Xuebijing in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease and its effects on immune function
10.3760/cma.j.issn.1008-6706.2018.22.002
- VernacularTitle:血必净对慢性阻塞性肺疾病急性加重期患者的临床疗效及免疫功能的影响
- Author:
Hongwei XIE
1
;
Lili YUE
;
Guoxin ZAN
Author Information
1. 洛阳市第一人民医院呼吸危重症科
- Keywords:
Pulmonary disease;
chronic obstructive;
Xuebijing injection;
T lymphocytes;
C reactive protein;
Calcitonin;
Immune function;
Controlled clinical trial
- From:
Chinese Journal of Primary Medicine and Pharmacy
2018;25(22):2861-2864
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the changes of T lymphocyte subsets in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD). To evaluate the clinical efficacy of Xuebijing injection in the treatment of AECOPD and its influence on T lymphocyte subsets. Methods From October 2016 to October 2017, 58 AECOPD patients and 20 healthy subjects at the same period in the First People's Hospital of Luoyang were selected. The levels of T - lymphocyte subsets were detected in healthy subjects and AECOPD patients. The 58 cases patients were divided into observation group(n = 28) and control group(n = 30) using random number table. The control group was treated with conventional therapy. The observation group was treated with Xuebijing injection on the basis of the control group. The scores of CAT,APACHE Ⅱ in both two groups before and after treatment were evaluatedThe levels of C - reactive protein(CRP),procalcitonin(PCT) and T lymphocyte subsets were compared between the two groups before and after treatment. Results The levels of CD +3 ,CD +4 and CD +4 / CD +8 in the peripheral blood of patients with AECOPD were (0. 64 ± 0. 10)％ ,(0. 33 ± 0. 14)％ and (0. 95 ± 0. 48),respectively,which of the healthy controls were (0. 70 ± 0. 10)％ , (0. 41 ± 0. 17)％ , (1. 25 ± 0. 51), respectively. There were statistically significant differences between the two groups(t = 2. 09,7. 19,2. 32,all P < 0. 05). After treatment,the scores of CAT and APACHE Ⅱ in the observation group were (13. 2 ± 3. 6)points and (14. 1 ± 3. 8)points,those in the control group were (16. 6 ± 4. 1) points and (16. 9 ± 4. 2) points. The scores of CAT and APACHE Ⅱ in the two groups after treatment were lower than those before treatment(observation group: t = 3. 08,13. 25,control group: t = 2. 94,11. 31,all P < 0. 05). There were significant differences in CAT and APACHE Ⅱ scores between the two groups after treat-ment(t = 8. 90,3. 27,all P < 0. 05). The levels of CRP,PCT,CD +3 ,CD +4 and CD +4 / CD +8 in the control group were (22. 4 ± 8. 8)mg/ L,(0. 9 ± 0. 6)μg/ L,(0. 67 ± 0. 09)％ ,(0. 36 ± 0. 13)％ ,(1. 12 ± 0. 50),respectively,which in the observation group were (15. 6 ± 6. 3)mg/ L,(0. 5 ± 0. 6)μg/ L,(0. 72 ± 0. 82)％ ,(0. 43 ± 0. 13)％ ,(1. 43 ± 0. 47),respectively. The differences between the two groups were statistically significant(t = 2. 75,6. 16,2. 03,2. 69, 4. 90,all P < 0. 05). Conclusion Patients with AECOPD have immune dysfunction. Xuebijing injection is effective in the treatment of patients with AECOPD. The mechanism may be related to the regulation of immune function.
